share_log

Invivyd | 10-Q: Q3 2024 Earnings Report

Invivyd | 10-Q: Q3 2024 Earnings Report

Invivyd | 10-Q:2024财年三季报
美股SEC公告 ·  2024/11/14 20:26

Moomoo AI 已提取核心信息

Invivyd reported Q3 2024 financial results, marking its first full quarter of PEMGARDA commercialization with net product revenue of $9.3M. The company recorded a net loss of $60.7M compared to $39.4M in Q3 2023, while R&D expenses increased to $57.9M from $25.6M YoY, primarily due to VYD2311 development costs.The company's cash position stood at $106.9M as of September 30, 2024, down from $200.6M at year-end 2023. In February 2024, Invivyd raised $39.3M through a stock offering. Operating expenses increased significantly, with total operating costs reaching $71.6M compared to $43.1M in Q3 2023, driven by commercialization activities and pipeline development.Management indicated substantial doubt about the company's ability to continue as a going concern beyond one year, citing the need for additional funding through revenues, equity offerings, or other financing sources. The company continues to advance its pipeline, including VYD2311 which entered Phase 1 trials, while focusing on PEMGARDA commercialization and maintaining its commitment to developing protection against viral infectious diseases.
Invivyd reported Q3 2024 financial results, marking its first full quarter of PEMGARDA commercialization with net product revenue of $9.3M. The company recorded a net loss of $60.7M compared to $39.4M in Q3 2023, while R&D expenses increased to $57.9M from $25.6M YoY, primarily due to VYD2311 development costs.The company's cash position stood at $106.9M as of September 30, 2024, down from $200.6M at year-end 2023. In February 2024, Invivyd raised $39.3M through a stock offering. Operating expenses increased significantly, with total operating costs reaching $71.6M compared to $43.1M in Q3 2023, driven by commercialization activities and pipeline development.Management indicated substantial doubt about the company's ability to continue as a going concern beyond one year, citing the need for additional funding through revenues, equity offerings, or other financing sources. The company continues to advance its pipeline, including VYD2311 which entered Phase 1 trials, while focusing on PEMGARDA commercialization and maintaining its commitment to developing protection against viral infectious diseases.
Invivyd发布了2024年第三季度财务报告,标志着其PEMGARDA商业化的第一个完整季度,净产品营业收入为930万美元。与2023年第三季度的3940万美元相比,公司录得了6070万美元的净亏损,而研发费用同比从2560万美元增加到5790万美元,主要由于VYD2311的开发成本。截至2024年9月30日,公司现金头寸为10690万美元,低于2023年年末的20060万美元。在2024年2月,Invivyd通过股票发行筹集了3930万美元。营业费用显著增加,总运营成本达7160万美元,而2023年第三季度为4310万美元,主要受商业化活动和管线开发的推动。管理层对公司能否在一年后继续作为持续经营单位表示重大怀疑,并提到需要通过营业收入、股权发行或其他融资来源获取额外资金。公司继续推进其管线,包括进入第一阶段试验的VYD2311,同时专注于PEMGARDA商业化,致力于开发对抗病毒感染性疾病的保护。
Invivyd发布了2024年第三季度财务报告,标志着其PEMGARDA商业化的第一个完整季度,净产品营业收入为930万美元。与2023年第三季度的3940万美元相比,公司录得了6070万美元的净亏损,而研发费用同比从2560万美元增加到5790万美元,主要由于VYD2311的开发成本。截至2024年9月30日,公司现金头寸为10690万美元,低于2023年年末的20060万美元。在2024年2月,Invivyd通过股票发行筹集了3930万美元。营业费用显著增加,总运营成本达7160万美元,而2023年第三季度为4310万美元,主要受商业化活动和管线开发的推动。管理层对公司能否在一年后继续作为持续经营单位表示重大怀疑,并提到需要通过营业收入、股权发行或其他融资来源获取额外资金。公司继续推进其管线,包括进入第一阶段试验的VYD2311,同时专注于PEMGARDA商业化,致力于开发对抗病毒感染性疾病的保护。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息